Publication:
ASEAN Capacity for Vaccine Research and Development and Production: Malaysia Country Case Study

Simple item page
dc.contributor.authorWorld Bank
dc.date.accessioned2023-09-20T20:13:06Z
dc.date.available2023-09-20T20:13:06Z
dc.date.issued2023-06-16
dc.description.abstractCOVID-19 has devastated the ASEAN region, threatening two decades of human and economic development gains. With a population of more than 600 million, the region has reported more than 13 million COVID-19 cases as of October 2021, with Indonesia, the Philippines, Malaysia, and Thailand leading in number of confirmed cases. In the absence of effective treatment options, vaccination and preventative behaviors remain cornerstones for ASEAN governments to stop COVID-19’s spread, save lives, and revive economies. Despite rapid innovation and development of mRNA, viral vector, and protein subunit vaccine technology platforms, low and middle-income countries (LMICs) continue to struggle to access vaccines. ASEAN countries have remained net importers of essential vaccines, notwithstanding strong potential for local research and manufacture. Consequently, COVID-19 vaccination coverage varies widely, ranging from 10 percent in Myanmar to 80 percent in Singapore. These disparities render the region vulnerable to new variants, surges, and vaccine escape. To contain COVID-19 and respond to future pandemics, ASEAN must build strong regional capacity to develop, test, and scale up manufacture of vaccines, building on country-level strengths and avoiding duplication. Galvanizing ASEAN vaccine development and manufacturing efforts aligns with the November 2019 declaration of ASEAN leaders on regional vaccine security and self-reliance.en
dc.identifierhttp://documents.worldbank.org/curated/en/099061623000028190/P1780920f78e97052086040eb877494ac69
dc.identifier.doi10.1596/40375
dc.identifier.urihttps://openknowledge.worldbank.org/handle/10986/40375
dc.languageEnglish
dc.language.isoen_US
dc.publisherWashington, DC: World Bank
dc.rightsCC BY-NC 3.0 IGO
dc.rights.holderWorld Bank
dc.rights.urihttps://creativecommons.org/licenses/by-nc/3.0/igo
dc.subjectCOVID-19
dc.subjectVACCINE
dc.subjectASEAN REGION
dc.titleASEAN Capacity for Vaccine Research and Development and Productionen
dc.title.subtitleMalaysia Country Case Studyen
dc.typeReport
dspace.entity.typePublication
okr.crossref.titleASEAN Capacity for Vaccine Research and Development and Production: Malaysia Country Case Study
okr.date.disclosure2023-06-16
okr.date.lastmodified2023-06-15T00:00:00Zen
okr.doctypeEconomic & Sector Work
okr.doctypeEconomic & Sector Work::Other Health Study
okr.docurlhttp://documents.worldbank.org/curated/en/099061623000028190/P1780920f78e97052086040eb877494ac69
okr.guid099061623000028190
okr.identifier.docmidP178092-f78e9796-0399-4252-8604-eb877494ac69
okr.identifier.doihttp://dx.doi.org/10.1596/40375
okr.identifier.externaldocumentum34094651
okr.identifier.internaldocumentum34094651
okr.identifier.report182880
okr.import.id1828
okr.importedtrueen
okr.language.supporteden
okr.pdfurlhttp://documents.worldbank.org/curated/en/099061623000028190/pdf/P1780920f78e97052086040eb877494ac69.pdfen
okr.region.administrativeEast Asia and Pacific
okr.region.countryMalaysia
okr.sectorHealth-HG
okr.themeHealth Systems and Policies,Human Development and Gender,Health Finance,Disease Control,Health System Strengthening,Pandemic Response
okr.topicHealth, Nutrition and Population::Immunizations
okr.unitHealth Nutrition &Population EAP (HEAHN)
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
P1780920f78e97052086040eb877494ac69.pdf
Size:
1.33 MB
Format:
Adobe Portable Document Format
Download
No Thumbnail Available
Name:
P1780920f78e97052086040eb877494ac69.txt
Size:
103.04 KB
Format:
Plain Text
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:
Download
Collections
Other Health Study